Roche launches NAVIFY Mutation Profiler and NAVIFY Therapy Matcher

Roche has launched the NAVIFY Mutation Profiler, a clinical software that provides annotation, interpretation and clinical reporting of next-generation sequencing tests, and the NAVIFY Therapy Matcher, an optional clinical decision support app that further aids clinicians in linking clinically actionable mutations to relevant therapy options.
The NAVIFY Mutation Profiler enables diagnostic labs to simplify how they report on their NGS tests, and facilitates better bridge precision diagnostics with personalized clinical management with NAVIFY Tumor Board, together with the integrated NAVIFY Clinical Decision Support apps. The NAVIFY Decision Support portfolio is capable of helping healthcare professionals navigate the complexity of medical and scientific information by transforming data into actionable insights, moving even closer to personalized healthcare.
Neil Gunn, Roche Sequencing Solutions head, said: “We are excited with the launch of NAVIFY Mutation Profiler and NAVIFY Therapy Matcher. Together they offer a clinical decision support solution that addresses a major workflow challenge for NGS labs, synthesizing large amounts of medical and scientific data into actionable insights.”